Barclays Issues Pessimistic Forecast for Clorox (NYSE:CLX) Stock Price

Clorox (NYSE:CLX) had its price objective lowered by research analysts at Barclays from $139.00 to $130.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “underweight” rating on the stock. Barclays‘s target price suggests a potential downside of 18.91% from the company’s previous close.

Several other equities analysts have also issued reports on the company. StockNews.com lowered Clorox from a “buy” rating to a “hold” rating in a research note on Sunday, January 5th. Jefferies Financial Group raised Clorox from a “hold” rating to a “buy” rating and boosted their target price for the stock from $174.00 to $187.00 in a research note on Tuesday, October 1st. TD Cowen upgraded shares of Clorox from a “sell” rating to a “hold” rating and raised their price target for the company from $155.00 to $170.00 in a research note on Wednesday, November 6th. Evercore ISI lowered their price objective on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating for the company in a research report on Monday, October 14th. Finally, DA Davidson raised their target price on shares of Clorox from $153.00 to $171.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $156.54.

Clorox Stock Down 0.1 %

Shares of CLX opened at $160.31 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08. Clorox has a 12 month low of $127.60 and a 12 month high of $171.37. The firm’s 50 day moving average is $164.25 and its 200-day moving average is $156.38. The stock has a market capitalization of $19.84 billion, a PE ratio of 55.86, a P/E/G ratio of 2.90 and a beta of 0.42.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.50. The firm had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.64 billion. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The company’s revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the company earned $0.49 EPS. Equities research analysts forecast that Clorox will post 6.87 EPS for the current year.

Hedge Funds Weigh In On Clorox

Several institutional investors have recently added to or reduced their stakes in the stock. Mizuho Securities USA LLC grew its position in shares of Clorox by 46,877.8% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock valued at $733,095,000 after acquiring an additional 4,490,421 shares during the period. Ilex Capital Partners UK LLP raised its holdings in shares of Clorox by 512.7% in the 3rd quarter. Ilex Capital Partners UK LLP now owns 542,110 shares of the company’s stock worth $88,315,000 after purchasing an additional 453,624 shares during the period. International Assets Investment Management LLC grew its holdings in Clorox by 424.9% during the third quarter. International Assets Investment Management LLC now owns 538,576 shares of the company’s stock valued at $877,390,000 after purchasing an additional 435,971 shares during the period. Boston Trust Walden Corp increased its position in Clorox by 5,442.5% in the third quarter. Boston Trust Walden Corp now owns 273,908 shares of the company’s stock worth $44,622,000 after buying an additional 268,966 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Clorox by 302.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 353,367 shares of the company’s stock valued at $57,390,000 after acquiring an additional 265,455 shares during the period. Institutional investors own 78.53% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.